Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00926731 · ClinicalTrials.gov registry record · Phase 1

Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)

A Phase 1 study of Acute Myeloid Leukemia, sponsored by AstraZeneca.

Completed
Registry status
Phase 1
Development phase
4
Enrollment target
4
Study locations

NCT00926731 is a Phase 1 study of Acute Myeloid Leukemia that has completed, run by AstraZeneca. The registered enrollment target is 4 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00926731, a Phase 1 study of Acute Myeloid Leukemia, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 1
Development phase
4 participants
Enrollment target
4
Study locations

Study Summary

A study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside (LDAC) in patients with acute myeloid leukaemia (AML). The first three patients to complete a 28 day cycle in the cohort, before the second three patients start treatment.

Conditions Studied

Acute Myeloid Leukemia

Interventions

  • DRUG AZD1152
  • DRUG LDAC (low dose cytosine arabinoside)

Study Locations (4)

Other

  • Research Site - Le Chesnay
  • Research Site - Villejuif

Ohio

  • Research Site - Cleveland

Texas

  • Research Site - Houston

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2009-06
Est. Completion 2011-05
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00926731

The ClinicalTrials.gov registry entry for NCT00926731 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (97% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which AZD1152 is the first listed.

NCT00926731 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Other, Ohio, Texas.

Frequently Asked Questions

What is clinical trial NCT00926731 about?

NCT00926731 is a clinical study titled "Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)". A study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside (LDAC) in patients with acute myeloid leukaemia (AML). The first three patients to complete a 28 day cycle in the cohort, before the second three patients start treatment.

What is the current status of trial NCT00926731?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2009-06. Estimated completion is 2011-05.

What conditions does trial NCT00926731 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia.

What interventions are being tested in trial NCT00926731?

The interventions under investigation include: AZD1152 (DRUG), LDAC (low dose cytosine arabinoside) (DRUG).

Who is sponsoring clinical trial NCT00926731?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00926731 being conducted?

This trial has 4 study locations across Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.